English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The standard of care for glioblastoma is surgical resection followed by adjuvant radiotherapy with concurrent and adjuvant temozolamide. However survival data and impact of temozolamide on survival in Indian population is scanty. Between January 2014 to December 2015, patients of glioblastoma who underwent surgery and had received post-operative radiotherapy(RT) with temozolomide(TMZ) were analyzed. A total of 16 patients who received RT/TMZ. Median overall survival (OS) of patients who received RT/TMZ was 11 months. On multivariate analysis age(p=0.005), KPS(p=0.05), extent of surgery(p=0.043) were found to affect survival. Concurrent radiotherapy and temozolamide followed by adjuvant temozolamide results in improved survival in glioblastoma. The benefit of temozolomide needs to be further evaluated by larger randomized trials in Indian population with particular emphasis on MGMT promoter methylation and other molecular markers.

iosr journal of dental and medical sciences

A Retrospective Study Evaluating Effectiveness of Concurrent And Adjuvant Temozolamide in Newly Diagnosed Glioblastoma Multiforme in Indian Population.